Xvivo Perfusion AB
STO:XVIVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (160.6), the stock would be worth kr526.02 (90% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 84.6 | kr277.2 |
0%
|
| 3-Year Average | 160.6 | kr526.02 |
+90%
|
| 5-Year Average | 103.3 | kr338.46 |
+22%
|
| Industry Average | 15.2 | kr49.71 |
-82%
|
| Country Average | 15.9 | kr52 |
-81%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
|
Xvivo Perfusion AB
STO:XVIVO
|
8.7B SEK | 84.6 | 347 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 37.2 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
59.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 17.4 | 37.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
91B DKK | 16.3 | 23.1 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.2B USD | 20.3 | 32.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 15.1 | 32.5 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 36.3 | -15.6 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.7B CNY | 19.3 | 22.2 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 21.2 | 51.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.6B CNY | 23.5 | 22.2 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 10.7 |
| Median | 15.9 |
| 70th Percentile | 23.7 |
| Max | 9 494.9 |
Other Multiples
Xvivo Perfusion AB
Glance View
Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted. Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.